Slide 1: Earnings Call – Q2 2021
Earnings Call – Q2 2021 August 5, 2021 Exhibit 99.2
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “w
Slide 3: Our mission: Treat and prove what others can't
Our mission: Treat and prove what others can’t. ©2021 ViewRay, Inc. All rights reserved.
Slide 4: What We Achieved: Q2 2021 financial results
What We Achieved Q2 2021 financial results 2Q 2020 2Q 2021 ©2021 ViewRay, Inc. All rights reserved.
Slide 5: Customers' Definition of Clinical Success
Customers’ Definition of Clinical Success MRIdian SMART: Stereotactic MR-guided Adaptive Radiotherapy Among alternatives in the clinical landscape, we have found only MRIdian’s evidence fits this criteria.1 Ablative Dose Tight Margins No Fiducials No or Low Grade 3 Toxicity The MRIdian 5 1 2 3 5 5 o
Slide 6: Recent Highlights: Innovation and clinical pipelines accrue customer traction
©2021 ViewRay, Inc. All rights reserved. + This presentation is intended for investors and analysts only. Some features described herein are not and may never be cleared or approved for sale in any markets. Recent Highlights Innovation and clinical pipelines accrue customer traction
Slide 7: Prospective studies and clinical trial program
Prospective studies. Larger ‘N’ Confirm signals in key tumor sites Safety and Efficacy endpoints Randomized controlled trials Comparative Safety and efficacy endpoints 60+ investigator-initiated trials Feasibility Explore new indications/expand SMART Reduce fx and improve workflow MIRAGE (CT vs. MRI
Slide 8: Prospective studies and clinical trial program
Prospective studies. Larger ‘N’ Confirm signals in key tumor sites Safety and Efficacy endpoints Randomized controlled trials Comparative Safety and efficacy endpoints 60+ investigator-initiated trials Feasibility Explore new indications/expand SMART Reduce fx and improve workflow MIRAGE (CT vs. MRI
Slide 9: Proving Economic and Strategic Value: Executive Customer Roundtable
©2021 ViewRay, Inc. All rights reserved. Proving Economic and Strategic Value Executive Customer Roundtable1 ” “Game-changer” “Mind-blowing” “Exceeded all expectations” “Truly transformative” “Patients came here because of the machine itself. ” Individual customer results are illustrative only and a
Slide 10: Proving Economic and Strategic Value
©2021 ViewRay, Inc. All rights reserved. Proving Economic and Strategic Value Executive Customer Roundtable1 Dana-Farber Brigham & Women’s Miami Cancer Institute 24% of patients from outside catchment area Almost doubled expected ROI in just 3 years “MRIdian is APM friendly” Technological differenti
Slide 11: More patients. More proof. More promise.
More patients. More proof. More promise. ©2021 ViewRay, Inc. All rights reserved. = Therapy Adoption + Program development Innovation Commercial Sub 20-minute treatment times Workflow Automation Enhanced MRI imaging Increased dosing Brain treatment package Remote access Cost reduction Incremental In
Slide 12: Financial Results Q2 2021
> VIEWRAY Financial Results Q2 2021
Slide 13: Financial Highlights
ASP of $6.1M excluding upgrades Backlog increased 20% YoY Strong customer engagement despite the challenges posed by the ongoing pandemic Operating Expenses effectively flat YoY R&D up 27% S&M flat G&A down 9% Revenue increased 6% U.S. revenue: $12.4 million Outside of U.S. revenue: $2.6 million Fin
Slide 14: FY 2021 Guidance
©2021 ViewRay, Inc. All rights reserved. FY 2020 FY 2021 GROWTH % Guidance (1) Excludes the January 2021 equity financing
Slide 15: ViewRay | Visibly Better
@ VIEW RAY |VISIBLY BETTER
Slide 16: Presentation Citations
Presentation Citations Slide 3 Internal and historical company data 06/30/2021 MRIdian log data Slide 5 Ablative dose, Tight margins, No fiducials: Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, Romaguera T, Rubens M, Adamson S, Godley A, Mishra V, Luciani G, Gutierrez AN, Ablative
Slide 17: Presentation Citations
Presentation Citations Slide 7 1. Phase 1 (Exploratory) - SMART ONE: Miami Cancer Institute, PI: Dr. Michael Chuong, “Stereotactic MRI-Guided Adaptive Radiation Therapy Delivered in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART One)” - SMART Master: https://clinicaltrials.gov/ct